Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician-patient survey.

Scientific reports·2026
Same author

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Cancers·2026
Same author

Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.

Current oncology (Toronto, Ont.)·2026
Same author

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Current oncology (Toronto, Ont.)·2026
Same author

Regarding: Nachira D, Calabrese G, Bertolaccini L, et al. Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer : Updates in Surgery, 2026, https://doi.org/10.1007/s13304-026-02605-x.

Updates in surgery·2026
Same author

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

JCO oncology practice·2026

Related Experiment Video

Updated: May 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study.

Sercan Ön1, Barış Köksal2, Zafer Arık2

  • 1Department of Medical Oncology, Tepecik Training and Research Hospital, 35180 Izmir, Türkiye.

Current Oncology (Toronto, Ont.)
|November 26, 2024
PubMed
Summary
This summary is machine-generated.

Trabectedin is effective for metastatic L-type sarcomas after anthracyclines. Local treatments and objective responses correlate with better outcomes, while dose reductions do not worsen survival in these rare cancers.

Keywords:
drug toxicityecteinascidin 743leiomyosarcomasliposarcomastargeted radiation therapytrabectedin

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

Related Experiment Videos

Last Updated: May 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

Area of Science:

  • Medical Oncology
  • Sarcoma Research
  • Pharmacology

Background:

  • Metastatic L-type sarcomas (liposarcoma, leiomyosarcoma) are rare with poor prognosis.
  • Trabectedin is an established treatment option following anthracycline therapy.

Purpose of the Study:

  • To evaluate the real-world effectiveness and safety of trabectedin in metastatic L-type sarcomas.
  • To identify prognostic factors influencing treatment outcomes.

Main Methods:

  • Retrospective multicenter study of 98 patients treated with trabectedin.
  • Evaluation of objective response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and overall survival (OS).
  • Cox regression analysis for prognostic factor identification.

Main Results:

  • ORR was 16%, DCR was 42%, median TTF was 3 months, and median OS was 10 months.
  • Local treatment and objective responses were associated with longer TTF.
  • Objective response was a positive prognostic factor for OS; liver metastases indicated a poor prognosis.

Conclusions:

  • Trabectedin is a viable treatment for L-type sarcoma post-anthracyclines.
  • Dose reductions did not negatively impact survival.
  • Combination of trabectedin with local therapies may enhance efficacy.